Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) is now available.
Shanghai Henlius Biotech, Inc. has announced that the U.S. FDA has approved two of its biosimilar products, BILDYOS® and BILPREVDA®, for eight indications related to osteoporosis and other bone conditions. This approval is based on comprehensive studies demonstrating the biosimilars’ similarity to the reference products in terms of quality, safety, and efficacy. The approval is expected to enhance the company’s market position and expand its global reach, particularly through its partnership with Organon LLC for commercialization outside of China.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$97.75 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development and commercialization of biosimilar products. The company specializes in creating treatments for various medical conditions, with a particular emphasis on biosimilars for osteoporosis and other bone-related diseases.
Average Trading Volume: 1,412,857
Technical Sentiment Signal: Buy
Current Market Cap: HK$42.34B
See more insights into 2696 stock on TipRanks’ Stock Analysis page.